Report
Michael Waterhouse
EUR 100.00 For Business Accounts Only

Fresenius Medical Care and Fresenius SE Both Preview Weaker-Than-Expected 2019 Outlook

Both Fresenius Medical Care and Fresenius SE previewed outlooks for 2019 below our expectations while also abandoning previous 2020 performance targets. While we had already assumed each company’s 2020 targets were unrealistic, the guidance for 2019 does fall short of our projections. We therefore anticipate modest reductions to our fair value estimates for both companies, but the recent sell-off in shares seems overdone, in our view. We don’t foresee dramatic changes to our longer-term assumpti...
Underlying
Fresenius SE & Co. KGaA

Fresenius is a health care group providing products and services for dialysis, hospitals and outpatient medical care. Co. operates four business segments: Fresenius Medical Care; Fresenius Kabi; Fresenius Helios; and Fresenius Vamed. Fresenius Medical Care provides dialysis care and dialysis products for patients with chronic kidney failure. Fresenius Kabi is engaged in the provision of generic drugs, infusion therapies, clinical nutrition products, related medical devices and transfusion technology. Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. Fresenius Helios is a private hospital operator which only operates in Germany.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Michael Waterhouse

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch